28 results
Thumbnail

D2.351 - Relapse Rate and Risk Factors After Omalizumab Treatment in Adolescents with Chronic Spontaneous Urticaria

Thumbnail

D2.352 - Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria

Thumbnail

D2.353 - A Single Dose of Briquilimab, An Anti-Human CD117 (c-Kit) Antibody, Protects Against Relapse of Epicutaneous Allergen-Induced Dermatitis in Mice Expressing Chimeric Human/Mouse CD117

Thumbnail

D2.354 - Questionnaire survey of new treatments for atopic dermatitis

Thumbnail

D2.355 - Concurrent use of dupilumab and omalizumab in severe atopic dermatitis and severe chronic urticaria

Thumbnail

D2.356 - Real-life effectiveness of omalizumab and its impact on quality of life in patients with chronic spontaneous urticaria

Thumbnail

D2.357 - Characterizing chronic histaminergic angioedema and chronic urticaria with angioedema, a multicenter Italian experience

Thumbnail

D2.358 - Immune shift toward the IL-17 pathway: A case of paradoxical psoriasis in a patient with severe atopic dermatitis induced by dupilumab

Thumbnail

D2.359 - Safety and effectiveness of Omalizumab for Cold Urticaria in pediatric age

Thumbnail

D2.362 - Dual biological therapy with dupilumab and ixekizumab in a patient with asthma, nasal polyposis, atopic dermatitis and psoriasis

Thumbnail

D2.363 - Lanadelumab Effect on Hereditary Angioedema Activity Score: A Tertiary Center Experience

Thumbnail

D2.364 - Omalizumab Use in Pediatric Chronic Urticaria, A Retrospective Study from a Tertiary Hospital

Thumbnail

D3.265 - Biphasic anaphylaxis secondary to polyethylene glycol in a pediatric patient: a case report

Thumbnail

D3.268 - Chronic Allergen Exposure Induces Accumulation of IgE Plasma Cells in the Lung, Leading to Local IgE Antibody Production

Thumbnail

D3.269 - Drug-Induced Anaphylaxis in Children: A Comparative Analysis of Inpatient vs. Outpatient Settings

Thumbnail

D3.270 - A novel workflow for cell metabolomics: impact of anaphylaxis in a human endothelial system

Thumbnail

D3.272 - Safety and Efficacy of Vancomycin and Other Antimicrobial Drug Desensitization in Pediatric Patients

Thumbnail

D3.273 - Assessing Anaphylaxis in COVID-19 vaccines: Application of amended Brighton Collaboration Criteria

Thumbnail

D3.274 - Succesful Omalizumab Desensitization in Two Children with Severe Allergic Asthma and Cronic Spontaneous Urticaria

Thumbnail

D3.275 - Anaphylaxis caused by polyhexanide